Drug development and medicinal chemistry efforts toward SARS‐coronavirus and Covid‐19 therapeutics
AK Ghosh, M Brindisi, D Shahabi… - …, 2020 - Wiley Online Library
The COVID‐19 pandemic caused by SARS‐CoV‐2 infection is spreading at an alarming
rate and has created an unprecedented health emergency around the globe. There is no …
rate and has created an unprecedented health emergency around the globe. There is no …
An updated review on SARS-CoV-2 main Proteinase (MPro): protein structure and small-molecule inhibitors
Coronaviruses (CoVs) are enveloped positive-stranded RNA viruses with spike (S) protein
projections that allow the virus to enter and infect host cells. The S protein is a key virulence …
projections that allow the virus to enter and infect host cells. The S protein is a key virulence …
Binding interaction of quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure–activity relationship studies reveal salient …
L Chen, J Li, C Luo, H Liu, W Xu, G Chen… - Bioorganic & medicinal …, 2006 - Elsevier
The 3C-like protease (3CLpro) of severe acute respiratory syndrome-associated coronavirus
(SARS-CoV) is one of the most promising targets for discovery of drugs against SARS …
(SARS-CoV) is one of the most promising targets for discovery of drugs against SARS …
Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease
IL Lu, N Mahindroo, PH Liang, YH Peng… - Journal of medicinal …, 2006 - ACS Publications
Severe acute respiratory syndrome coronavirus (SARS-CoV) main protease (Mpro), a
protein required for the maturation of SARS-CoV, is vital for its life cycle, making it an …
protein required for the maturation of SARS-CoV, is vital for its life cycle, making it an …
[HTML][HTML] Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
JW Kim, EJ Kim, HH Kwon, CY Jung… - The Korean journal …, 2020 - pmc.ncbi.nlm.nih.gov
Background/Aims The efficacies of lopinavir-ritonavir or hydroxychloroquine remain to be
determined in patients with coronavirus disease 2019 (COVID-19). To compare the …
determined in patients with coronavirus disease 2019 (COVID-19). To compare the …
Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus
LE Hsieh, CN Lin, BL Su, TR Jan, CM Chen, CH Wang… - Antiviral research, 2010 - Elsevier
Feline infectious peritonitis (FIP) is a fatal disease in domestic and nondomestic felids
caused by feline coronavirus (FCoV). Currently, no effective vaccine is available for the …
caused by feline coronavirus (FCoV). Currently, no effective vaccine is available for the …
Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections
TR Tong - Infectious Disorders-Drug Targets (Formerly Current …, 2009 - ingentaconnect.com
Coronaviruses are important human and animal pathogens of the order Nidovirales. Several
new members were discovered following the emergence of SARS-CoV in human …
new members were discovered following the emergence of SARS-CoV in human …
Development of anti-viral agents using molecular modeling and virtual screening techniques
J Kirchmair, S Distinto, K Roman Liedl… - … Current Drug Targets …, 2011 - ingentaconnect.com
Computational chemistry has always played a key role in anti-viral drug development. The
challenges and the quickly rising public interest when a virus is becoming a threat has …
challenges and the quickly rising public interest when a virus is becoming a threat has …
Monoamine transporter structure, function, dynamics, and drug discovery: a computational perspective
S Manepalli, CK Surratt, JD Madura, TL Nolan - The AAPS journal, 2012 - Springer
With the breakthrough crystallization of the bacterial leucine transporter protein LeuT, the
first available X-ray structure for the neurotransmitter/sodium symporter family, development …
first available X-ray structure for the neurotransmitter/sodium symporter family, development …
A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of …
U Kaeppler, N Stiefl, M Schiller, R Vicik… - Journal of medicinal …, 2005 - ACS Publications
The coronavirus main protease, Mpro, is considered to be a major target for drugs suitable
for combating coronavirus infections including severe acute respiratory syndrome (SARS) …
for combating coronavirus infections including severe acute respiratory syndrome (SARS) …